Skip to main content

Rare eye condition

Cancer-associated retinopathy

Cancer-associated retinopathy (CAR) is a rare paraneoplastic condition in which antibodies produced against a tumour cross-react with the retina, causing rapidly progressive visual loss - sometimes before the cancer is found.

Key points

The essentials at a glance.

What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.

  • 01

    Symptoms evolve over weeks to months: shimmering, glare, night blindness, tunnel vision and falling acuity in both eyes.

  • 02

    The retina can initially look normal; ERG is profoundly abnormal - the key test.

  • 03

    Anti-retinal antibodies (classically anti-recoverin) support the diagnosis.

  • 04

    Small-cell lung cancer is the commonest association; CAR can precede the cancer diagnosis, mandating a thorough malignancy search.

  • 05

    Treatment combines managing the tumour with immunosuppression (steroids, IVIG, rituximab), though visual recovery is limited - early diagnosis matters.

Understanding it

What it is, and what happens next.

In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.

In CAR the immune response mounted against a cancer misfires: retinal proteins resemble tumour antigens, and the antibodies attack photoreceptors in both eyes. The clinical clue is bilateral, unexplained, rapidly progressive visual loss with a disproportionately extinguished ERG - a picture no common eye disease produces at that pace.

The dual task is urgent: confirm the retinal diagnosis with electrophysiology and antibody testing, and hunt for the underlying malignancy with imaging of chest, abdomen and beyond, since in a significant fraction the eye disease is the cancer's first announcement; treatment is then coordinated between oncology and specialist ophthalmology.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.

Published 2026-09-27 · Next review 2027-09-27

Frequently asked

Common questions about Cancer-associated retinopathy.

Quick, plain-English answers to what people ask us most.

  • What is cancer-associated retinopathy?

    Cancer-associated retinopathy is a cancer that develops when abnormal cells in the affected tissue grow and divide out of control. It can range from a small, early-stage growth confined to one area to more advanced disease that has spread to nearby structures or further afield. A tissue biopsy, blood tests and imaging are usually needed to confirm the diagnosis and work out the stage.

  • Why does cancer-associated retinopathy happen?

    Like most cancers, cancer-associated retinopathy develops when genetic changes build up in cells over time, causing them to grow abnormally and evade the body's normal controls. Age, lifestyle factors, environmental exposures and, in some cases, inherited genetic variants can all contribute. Often no single clear cause can be identified in an individual case.

  • What are the symptoms of cancer-associated retinopathy?

    Symptoms of cancer-associated retinopathy vary from person to person and depend on how severe the condition is and which structures are affected. Some people notice symptoms gradually over weeks or months, while others experience a more sudden onset. Because symptoms can overlap with other conditions, a proper assessment is important to reach an accurate diagnosis rather than relying on symptoms alone.

  • Is cancer-associated retinopathy serious?

    Cancer-associated retinopathy should always be taken seriously, but the outlook varies enormously depending on the stage at diagnosis, the specific type of cancer involved, and how well it responds to treatment. Many cases caught at an early stage can be treated very effectively. Prompt investigation of any concerning symptoms gives the best chance of early diagnosis.

  • Is cancer-associated retinopathy hereditary or genetic?

    Some cases of cancer-associated retinopathy have a genetic component and can run in families, while others occur without any family history at all. Having a relative with the condition may modestly increase your own risk, but it does not mean you will definitely develop it yourself. If you are concerned about a family history, mention this to your doctor, as it may occasionally influence screening or monitoring.

  • Can cancer-associated retinopathy be cured?

    Many cases of cancer-associated retinopathy can be treated very successfully, particularly when caught early, and some people are cured completely. Others may need ongoing treatment to control the disease and manage symptoms over the longer term. Your oncology team will be able to give you a much clearer picture based on your specific type and stage.

  • How is cancer-associated retinopathy treated?

    Treatment for cancer-associated retinopathy is tailored to the individual and depends on severity, underlying cause and personal circumstances. Options can range from simple lifestyle measures, monitoring and conservative treatment through to medication, specialist procedures or surgery in more significant cases. A specialist assessment helps identify which combination of treatments is most appropriate for you.

  • How long does cancer-associated retinopathy last?

    The duration of cancer-associated retinopathy varies considerably: some people recover within days or weeks, while others live with a more persistent or recurring condition that needs ongoing management. Response to treatment, how early it is started, and individual factors all influence the timescale. Your clinician can give you a more personalised estimate once your specific circumstances are known.

  • When is surgery needed for cancer-associated retinopathy?

    Surgery is not usually the first option for cancer-associated retinopathy and is generally reserved for cases where conservative treatment has not worked, symptoms are severe, or there is a significant structural problem that needs to be corrected directly. The decision depends on your specific findings, symptoms and how they are affecting your life. A specialist consultation is the best way to establish whether surgery is being considered too early, or should be considered sooner rather than later.

  • When should I see a doctor about cancer-associated retinopathy, and how quickly can I be seen privately?

    It is worth seeing a doctor about cancer-associated retinopathy if symptoms are persistent, getting worse, or affecting your daily life, rather than waiting to see if they settle on their own. NHS routine referrals to a specialist can currently take anywhere from around 20 to 45 weeks or more depending on your area, whereas a private consultant can typically see you within about 2 weeks. Getting an earlier assessment can help clarify the diagnosis and start the right treatment sooner.